0.00Open0.17Pre Close0 Volume1 Open Interest0.50Strike Price0.00Turnover1709.54%IV86.13%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type-0.0387Delta0.0193Gamma14.00Leverage Ratio-0.0465Theta0.0000Rho-0.54Eff Leverage0.0002Vega
Esperion Therapeutics Stock Discussion
money flow is like a lazy cat... what sign is this?
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
No comment yet